- Home
- ENVB vs MITQ Comparison
ENVB vs MITQ Comparison
Compare ENVB & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENVB | MITQ |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.2M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ENVB | MITQ |
|---|---|---|
| Price | $1.40 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 57.2K | ★ 104.4K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 70.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,914,675.00 | $20,139,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $0.42 |
| 52 Week High | $795.00 | $1.03 |
Technical Indicators
Market Signals| Indicator | ENVB | MITQ |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 43.87 |
| Support Level | $1.37 | $0.52 |
| Resistance Level | $1.53 | $0.61 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 32.92 | 18.81 |
Price Performance
Historical ComparisonAbout ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.